RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%
February 14, 2020 08:11 ET
|
RECORDATI
RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%. Consolidated revenues € 1,481.8 million, +9.6%.EBITDA (1) € 544.0 million,...
RECORDATI: APPROVAZIONE DI ISTURISA® (OSILODROSTAT)
January 15, 2020 06:13 ET
|
RECORDATI
RECORDATI: APPROVAZIONE DI ISTURISA® (OSILODROSTAT) Milano, 15 gennaio, 2020 - Recordati annuncia che la Commissione Europea ha approvato l’immissione in commercio del prodotto farmaceutico orfano...
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED
January 15, 2020 06:13 ET
|
RECORDATI
RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED Milan, 15 January, 2020 – Recordati announces that the European Commission has granted marketing authorisation for the orphan medicinal product Isturisa®...
RECORDATI: IL CHMP EMETTE OPINIONE POSITIVA PER L’APPROVAZIONE DI ISTURISA® (OSILODROSTAT)
November 15, 2019 11:34 ET
|
RECORDATI
Milano, 15 novembre 2019 – Recordati annuncia che l’EMA (Eurpean Medicines Agency) ha comunicato a Novartis che il Committe for Medicianl Products for Human Use (CHMP) ha emesso una opinione positiva,...
RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT)
November 15, 2019 11:34 ET
|
RECORDATI
RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT) Milan, 15 November 2019 – Recordati announces that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive...
RECORDATI: RISULTATI ECONOMICI IN CRESCITA NEI PRIMI NOVE MESI DEL 2019. RICAVI +8,6%, EBITDA +7,8%, UTILE OPERATIVO +4,9%, UTILE NETTO +6,6%. ACCONTO DIVIDENDO € 0,48 (+6,7%).
October 31, 2019 08:01 ET
|
RECORDATI
RECORDATI: RISULTATI ECONOMICI IN CRESCITA NEI PRIMI NOVE MESI DEL 2019. RICAVI +8,6%, EBITDA +7,8%, UTILE OPERATIVO +4,9%, UTILE NETTO +6,6%. ACCONTO DIVIDENDO € 0,48 (+6,7%). Ricavi netti...
RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%).
October 31, 2019 08:01 ET
|
RECORDATI
RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%). Consolidated revenues € 1,100.4...
RECORDATI: CONCLUSA L’ACQUISIZIONE DEI DIRITTI PER SIGNIFOR® E OSILODROSTAT (LCI699) A LIVELLO MONDIALE
October 23, 2019 06:06 ET
|
RECORDATI
RECORDATI: CONCLUSA L’ACQUISIZIONE DEI DIRITTI PER SIGNIFOR® E OSILODROSTAT (LCI699) A LIVELLO MONDIALE Milano, 23 ottobre 2019 – Recordati comunica che è stata conclusa con successo l’acquisizione...
RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED
October 23, 2019 06:06 ET
|
RECORDATI
RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED Milan, 23 October 2019 – Recordati announced the successful completion of the acquisition from Novartis of...
RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%
July 30, 2019 07:21 ET
|
RECORDATI
RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1% ·Consolidated revenues € 743.3 million, +6.8%.·EBITDA (1) € 279.3 million, +7.4%·Operating income...